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Abstract
Introduction: Prediction of massive transfusion (MT) among trauma patients is difficult in the early phase of
trauma management. Whole-blood thromboelastometry (ROTEM
®) tests provide immediate information about the
coagulation status of acute bleeding trauma patients. We investigated their value for early prediction of MT.
Methods: This retrospective study included patients admitted to the AUVA Trauma Centre, Salzburg, Austria, with
an injury severity score ≥16, from whom blood samples were taken immediately upon admission to the
emergency room (ER). ROTEM
® analyses (extrinsically-activated test with tissue factor (EXTEM), intrinsically-activated
test using ellagic acid (INTEM) and fibrin-based extrinsically activated test with tissue factor and the platelet
inhibitor cytochalasin D (FIBTEM) tests) were performed. We divided patients into two groups: massive transfusion
(MT, those who received ≥10 units red blood cell concentrate within 24 hours of admission) and non-MT (those
who received 0 to 9 units).
Results: Of 323 patients included in this study (78.9% male; median age 44 years), 78 were included in the MT
group and 245 in the non-MT group. The median injury severity score upon admission to the ER was significantly
higher in the MT group than in the non-MT group (42 vs 27, P < 0.0001). EXTEM and INTEM clotting time and clot
formation time were significantly prolonged and maximum clot firmness (MCF) was significantly lower in the MT
group versus the non-MT group (P < 0.0001 for all comparisons). Of patients admitted with FIBTEM MCF 0 to 3
mm, 85% received MT. The best predictive values for MT were provided by hemoglobin and Quick value (area
under receiver operating curve: 0.87 for both parameters). Similarly high predictive values were observed for
FIBTEM MCF (0.84) and FIBTEM A10 (clot amplitude at 10 minutes; 0.83).
Conclusions: FIBTEM A10 and FIBTEM MCF provided similar predictive values for massive transfusion in trauma
patients to the most predictive laboratory parameters. Prospective studies are needed to confirm these findings.
Introduction
Trauma-induced coagulopathy (TIC) affects 25 to 34%
of all trauma patients upon emergency room (ER)
admission and can be observed even before fluid resus-
citation [1-3]. TIC increases the risk of massive transfu-
sion (MT) which is associated with mortality rates up to
54% [1,4-6].
MT occurs in approximately 2 to 12% of civilian
trauma patients and up to 43% of combat casualties
[4,6-8]. Early identification of patients at risk of MT
would minimize the risk of treatment delay. Standard
coagulation tests (for example, prothrombin time (PT)
or Quick value, activated partial thromboplastin time
(aPTT), fibrinogen concentration) have typical turn-
around times around 30 to 60 minutes or longer [9,10].
Consequently, they are of limited value for early predic-
tion of MT; a turnaround time of ≤15 minutes would be
preferable. Scoring systems for identifying patients pos-
sibly requiring MT have been developed; these include
parameters such as blood pressure, heart rate and/or
laboratory findings which are available without delay
after ER admission [1,4,7,11-14]. However, such systems
do not provide information on coagulation status.
Thromboelastometry (ROTEM
®;T e mI n t e r n a t i o n a l
GmbH, Munich, Germany) offers rapid, comprehensive
assessment of the patient’sc o a g u l a t i o ns t a t u s ,f r o m
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potential breakdown of the clot [5,15-19]. ROTEM
® test
results have also been used to guide coagulation therapy
[20-22]. We hypothesized whether ROTEM
® tests could
potentially help identify patients who are prone to TIC
and MT immediately upon arrival at the trauma centre.
An investigation by Leemann et al.w a sd e s i g n e dt o
answer the same question [5], although in that study
coagulation therapy was based on allogeneic blood com-
ponents. In our centre we primarily use coagulation fac-
tor concentrates, which reduces transfusion of allogeneic
blood products [21] and, therefore, changes the basis for
predicting MT.
The primary aim of this study was to assess the pre-
dictive value of ROTEM
® parameters for MT among
trauma patients treated with coagulation factor concen-
trates, with ROTEM
® analyses performed on samples
taken immediately upon admission to the ER. The sec-
ondary aim was to compare the predictive value of
ROTEM
® parameters with the predictive value of stan-
dard coagulation tests.
Materials and methods
After approval from the local Ethics Committee (refer-
ence number 415-EP/73/5-2011), we performed a retro-
spective analysis of data from patients admitted to the
AUVA Trauma Centre Salzburg, Austria, between Janu-
ary 2005 and December 2010. All patients with an injury
severity score (ISS) ≥16, from whom blood samples were
taken immediately upon admission to the ER, were eligi-
ble for inclusion in the study. Exclusion criteria were as
follows: ISS <16; therapy withheld due to non-survivable
injuries; patient suffered from burns; patient transferred
from other hospitals. According to the decision of the
local Ethics Committee, no patient informed consent
was needed for this retrospective analysis.
Demographic data and clinical findings (blood pres-
sure (BP), heart rate (HR), temperature, ISS and Glas-
gow coma scale (GCS) score) upon admission to the ER
were collected from the anesthesia charts. ROTEM
®
measurements (from EXTEM, INTEM, and FIBTEM
tests performed on the samples taken upon ER admis-
sion) and standard coagulation test results were
reviewed.
ROTEM
® and standard coagulation tests
Blood samples for both ROTEM
® analysis and standard
coagulation tests were collected in 3 mL tubes contain-
ing 0.3 mL buffered 3.2% trisodium citrate (volume ratio
1:9). Thromboelastometric analyses were typically per-
formed at the bedside within minutes of sample collec-
tion by the attending anesthetist or intensivist. The
more severe the trauma, the more quickly the analyses
were undertaken (minimum set-up time approximately
two minutes). Three ROTEM
® tests were performed:
extrinsically activated assay with tissue factor (EXTEM),
intrinsically activated test using kaolin (INTEM), and
extrinsically activated test with tissue factor and the pla-
telet inhibitor cytochalasin D (FIBTEM).
For the EXTEM and INTEM assays, the following
variables were measured: clotting time (CT (s)); clot for-
mation time (CFT (s)); A10 (clot amplitude 10 minutes
after the end of CT); and maximum clot firmness (MCF
(mm)). For the FIBTEM assay, A10 and MCF were
investigated. The platelet component was calculated as
MCEEXTEM -M C E FIBTEM, where maximum clot elasti-
city MCE = (MCF*100)/(100-MCF) [23]. Finally, the
lysis index at 60 minutes (LI60 (%), clot firmness 60
minutes after CT as percentage of MCF) was collected
for the EXTEM and INTEM assays. Hyperfibrinolysis
was defined as complete breakdown of the clot, in
accordance with previous work by our group [24].
In parallel, standard laboratory analyses were per-
formed: Quick value and aPTT (determined on Sysmex
XE-2100 (Roche Diagnostics GmbH, Mannheim, Ger-
many)); pH, base deficit (BD) and lactate (analyzed
using Roche OMNI
® S Blood Gas Analyzer (Roche
Diagnostics GmbH); normal range for BD, −3.0 to +3.0
mmol/L; normal range for lactate 0.5 to 2.2 mmol/L).
Fibrinogen concentration was measured by the Clauss
method (STA-Fib
® a s s a y( R o c h eD i a g n o s t i c sG m b H ) ;
optical read-out), using a STA-Compact
® machine
(Roche Diagnostics GmbH, Vienna, Austria). Hemoglo-
bin, hematocrit and platelet count were analyzed using
blood samples anti-coagulated with ethylenediamine
tetra-acetic acid, with an SF 3000 analyzer (Sysmex Cor-
poration, Kobe, Japan).
Coagulation therapy, RBC administration and data
management
For patients with ongoing bleeding, coagulation therapy
was based on ROTEM
® test results with administration
of coagulation factor concentrates as previously
described [20,21]. Red blood cells (RBCs) were adminis-
tered as required to maintain a target intra-operative
hemoglobin concentration of 10 g/dL; later during
intensive care unit (ICU) therapy, a lower cut-off value
of 7 g/dL was accepted.
Since 2006, electronic documentation has been imple-
mented in our hospital where the type, amount and tim-
ing of allogeneic blood products transfused are recorded.
For 2005, the amount and timing of allogeneic blood
transfusion were reviewed from anesthesia and ICU
records. Two groups of patients were defined according
to RBC transfusion: non-massive transfusion (non-MT)
group (0 to 9 U RBC transfused in 24 hours), and mas-
sive transfusion (MT) group (≥10 U RBC transfused in
24 hours). This definition of MT is consistent with that
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expectation that the two patient groups would be well
matched, since patients with more severe injury upon
admission are more likely to undergo MT. Also, the
number of patients in the two groups was unlikely to be
equal, as in our centre <50% of patients undergo MT;
the inclusion of all eligible patients minimizes the risk
of bias.
Statistical analysis
Data are presented as mean ± standard deviation or med-
ian and interquartile range (IQR) for continuous vari-
ables, and as percentages for categorical variables.
Continuous variables were analyzed for normal distribu-
tion by the Kolmogorov-Smirnov test. To detect differ-
ences between patient groups, either the Student’s t-test
or the Mann-Whitney U-Test was performed, depending
on the underlying distribution. Group differences were
compared by ANOVA with the Kruskal-Wallis test. For
categorical variables, Fisher’s exact test was used. Corre-
lation between parameters was analyzed by Spearman’s
correlation coefficient rho. As a measure for discrimina-
tion not depending on a certain cut-off point, the area
under the receiver operating characteristic (ROC) curve
was determined, together with its 95% confidence inter-
val. A P-value <0.05 was considered significant for all sta-
tistical tests. Statistical calculations were performed using
GraphPad Prism 5.03 (GraphPad Software, La Jolla, CA,
USA) and IBM SPSS 19 (SPSS Inc., Chicago, IL, USA).
Results
During the six-year study period, 415 trauma patients
were identified as eligible for inclusion in the study. Of
these, 75 patients with ISS <16 and 17 patients with
advanced therapy withheld due to non-survivable inju-
ries were excluded. The remaining 323 patients were
included in the study.
Patients were predominantly male (78.9%) and the
median age was 44 (IQR: 26 to 59) years. Demographic
data, clinical findings on admission, GCS score at site of
accident and ISS for the three groups are outlined in
Table 1. The MT group comprised 78 patients, while
245 patients were in the non-MT group. Patients in the
MT group had significantly lower BP, higher HR, and
higher ISS values upon admission to the ER compared
with patients in the non-MT group. Mortality for the
whole study group was 19.8% (n = 64), with a signifi-
cantly higher rate in the MT group (Table 1).
Differences in coagulation status between transfusion
groups
ROTEM
® test results
ROTEM
® test results are outlined in Table 2. Significant
differences for all ROTEM
® variables upon arrival at the
ER were observed between the groups except for
E X T E Ml y s i si n d e x( L I ) .E X T E Ma n dI N T E MC Ta s
well as EXTEM and INTEM CFT were significantly pro-
longed in the MT group (P <0 . 0 1 ) .C o m p a r e dw i t ht h e
non-MT group, patients in the MT group had signifi-
cantly lower EXTEM MCF, INTEM MCF and FIBTEM
MCF. The data shown in Figure 1 allow comparison of
the amplitude after 10 minutes (A10) with the MCF
amplitude. In the FIBTEM assay, the difference between
median A10 and MCF was 1 mm in the MT group and
2 mm in the non-MT group. The platelet component
was significantly lower in the MT group compared with
the non-MT group (Table 2).
Hyperfibrinolysis was observed in 19 patients (5.9%);
14 (75%) of these patients died. A significant difference
between the study groups in LI was only observed with
the INTEM test (Table 2).
Standard laboratory results
Values for laboratory parameters on admission to the
ER are depicted in Table 3. The MT group showed
Table 1 Demographic and clinical data on arrival at the emergency room
non-MT group
(<10 RBC units/24 hours)
MT group
(≥10 RBC units/24 hours)
n = 245 n = 78 P-value
Age (years) 43 (24 to 58) 43 (23 to 61) ns
Male (n (%)) 198 (81%) 57 (73%) -
SBP (mmHg) 110 (90 to 130) 65 (55 to 80) <0.0001
HR (beats per minute) 90 (77 to 110.5) 120 (100 to 125) <0.0001
ISS 27 (20 to 34) 42 (34 to 50) <0.0001
GCS score at accident site 12 (6 to 15) 8 (3 to 12) 0.0006
RSI in the field (n (%)) 47 (19.2%) 51 (65.4%) 0.008
Temperature (°C) 35 (34 to 36) 35 (34 to 36) ns
Mortality (n) 32 (13.1%) 32 (41.2%) <0.0001
GCS, Glasgow Coma Scale; HR; heart rate; ISS, Injury Severity Score; MT, massive transfusion; non-MT, non-massive transfusion; RBC, red blood cell concentrate; n,
number of patients; ns, not significant; RSI, rapid sequence intubation; SBP, systolic blood pressure. Data are presented as median and interquartile range or n
(%). Groups were compared using the Kruskal-Wallis test.
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of 95 mg/dL. Correspondingly, Quick values and aPTT
showed significantly greater impairment of coagulation
in the patients who received MT. Blood gas analyses
and lactate levels were also significantly different
between the groups (P < 0.0001).
Prediction of massive transfusion: ROC curves
ROC curves for ROTEM
® parameters showed that the
best predictive value for MT was provided by FIBTEM
MCF (area under the curve (AUC) 0.84), with a similar
outcome for FIBTEM A10 (AUC 0.83) (Table 4). For
A10, a threshold of ≤4 mm provided the best values for
sensitivity (63.6, 95% confidence interval (CI) 51.9 to
74.3) and specificity (82.9, CI 77.5 to 87.5). The corre-
sponding threshold for MCF was ≤7 mm (sensitivity
78.2 (CI 67.4 to 86.8); specificity 74.7 (CI 68.7 to 80.1)).
AUCs for prediction by the EXTEM and INTEM test
parameters were slightly lower than those for FIBTEM
MCF and FIBTEM A10 (Table 4). A statistically signifi-
cant difference was observed between AUCs for FIB-
TEM MCF and INTEM MCF (P = 0.047), but there was
no significant difference between the AUCs for FIBTEM
A10 and INTEM MCF or EXTEM MCF. For all
ROTEM
® parameters, the ROC-AUC remained
unchanged if clot elasticity was used instead of clot
firmness (for example, maximum clot elasticity (MCE)
instead of MCF). The platelet component had an AUC
for MT prediction of 0.74 (CI 0.69 to 0.79).
Considering standard laboratory coagulation analyses,
the highest predictive values for MT were provided by
hemoglobin, Quick value and aPTT (ROC-AUC values
shown in Table 4). Fibrinogen concentration provided
predictive value similar to that of the FIBTEM
parameters.
Relationship between coagulation analyses and
transfusion
Quantities for RBC transfusion and coagulation therapy
within the first 24 hours are summarized in Table 5.
Patients in the MT group (by definition receiving more
units of RBC) also received higher amounts of fibrino-
gen concentrate (FC), prothrombin complex concentrate
(PCC) and platelet concentrate. Fresh frozen plasma
(FFP) administration is not outlined in the table as it
was used in only 10 out of 323 patients.
Higher amounts of RBC transfusion were observed
among patients with lower FIBTEM A10 values (P <
0.01) and lower fibrinogen concentration (Figure 2).
Using a cut-off value for FIBTEM A10 of ≤4 mm,
patients received a median of 10 (IQR 5 to 15) units of
RBC, compared to a median of 2 (IQR 0 to 6) units in
patients with a FIBTEM A10 >4 mm, representing five-
fold higher RBC transfusion among those with the lower
Table 2 ROTEM
® data on arrival at the emergency room
non-MT group
(<10 RBC units/24 hours)
MT group
(≥10 RBC units/24 hours)
n = 245 n = 78 P-value
EXTEM
CT (sec) 67 (56 to 90) 91 (73 to 129) <0.0001
CFT (sec) 116 (92 to 148) 189 (128 to 264) <0.0001
A10 (mm) 48 (42 to 54) 37 (29 to 46) <0.0001
MCF (mm) 57 (51 to 62) 48 (41 to 55) <0.0001
LI60 (%) 92 (88 to 95) 92 (88 to 96) ns
INTEM
CT (sec) 147 (133 to 167) 179 (148 to 220) <0.0001
CFT (sec) 85 (68 to 109) 163 (111 to 254) <0.0001
A10 (mm) 50 (43 to 55) 37 (31 to 47) <0.0001
MCF (mm) 57 (53 to 62) 48 (41 to 56) <0.0001
LI60 (%) 93 (90 to 95) 91 (73 to 94) 0.003
FIBTEM
A10 (mm) 9 (6 to 12) 4 (0 to 6) <0.0001
MCF (mm) 11 (7 to 14) 5 (0 to 7) <0.0001
Platelet component
MCEEXTEM - MCEFIBTEM 120 (95 to 148) 89 (68 to 114) <0.0001
Data are presented as median and interquartile range. Groups were compared using the Kruskal-Wallis test. A10, clot amplitude 10 minutes after CT; CFT, clot
formation time; CT, clotting time; EXTEM, extrinsically activated thromboelastometric test; FIBTEM, extrinsically activated thromboelastometric test with
cytochalasin D; INTEM, intrinsically activated thromboelastometric test; LI60, lysis index 60 minutes after CT; MCE, maximum clot elasticity; MCF, maximum clot
firmness; MT, massive transfusion; n, number of patients; non-MT, non-massive transfusion; ns, not significant; RBC, red blood cell concentrate.
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® measurements differed between patients who received massive transfusion and those that did not. Clot amplitude of
EXTEM, INTEM and FIBTEM in five minute intervals for patients who received or did not receive massive transfusion. For each test, after 10
minutes, 75 to 90% of the entire MCF is reached. A5 to A30, amplitude at five-minute intervals; EXTEM, extrinsically activated
thromboelastometric test; FIBTEM, extrinsically activated thromboelastometric test with cytochalasin D; INTEM, intrinsically activated
thromboelastometric test; MCF, maximum clot firmness; MT, massive transfusion. Groups were compared using the Kruskal-Wallis test. * P <
0.0001 between groups.
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≤3 mm, 26 (84%) were in the MT group. Unsurprisingly,
significant correlations were observed between FIBTEM
A10 and fibrinogen concentration (Spearman’s correla-
tion coefficient rho 0.78, P < 0.0001), and between MCF
and fibrinogen concentration (Spearman’s correlation
coefficient rho 0.75, P < 0.0001). Twenty-nine patients
had FIBTEM A10 values of zero and a median fibrino-
gen concentration of 64 mg/dL (IQR 54 to 94 mg/dL;
Figure 2c). In 17 of these patients, ‘spindle’ traces (LI
values up to 100%) for the INTEM and EXTEM assays
indicated the presence of hyperfibrinolysis.
Discussion
In this study, FIBTEM A10 and FIBTEM MCF showed
similar predictive values for MT among trauma patients
to those observed for the most predictive laboratory
parameters (hemoglobin, Quick value, aPTT, fibrinogen
concentration). Unlike the laboratory parameters,
ROTEM
® tests provide valuable information on overall
coagulation status and can be performed rapidly; conse-
quently, they have the potential to help guide hemo-
static therapy. On this basis, we advocate integration of
viscoelastic testing into protocols for initial assessment
of trauma patients.
Table 3 Standard laboratory parameters on arrival at the emergency room
non-MT group
(<10 RBC units/24 hours)
MT group
(≥10 RBC units/24 hours)
n = 245 n = 78 P-value
Hemoglobin
(normal range: 13.5 to 17 g/dL)
12.1 (10.7 to 13.4) 8.4 (6.9 to 10) <0.0001
Platelet count
(normal range: 150 to 350 × 10
3/μl)
188 (158 to 234) 150 (123 to 185) <0.0001
Quick value (normal range: 70 to 120%) 75 (65 to 88) 47 (36 to 60) <0.0001
aPTT (normal range: 26 to 35 s) 28 (26 to 32) 45 (36 to 60) <0.0001
Fibrinogen
(normal range: 200 to 450 mg/dL)
182 (134 to 236) 95 (61.5 to 121) <0.0001
Lactate
(normal range: 0.5 to 2.2 mmol/L)
2.2 (1.3 to 3.3) 4.4 (2.6 to 6.0) <0.0001
pH (normal range: 7.35 to 7.45) 7.33 (7.29 to 7.38) 7.23 (7.19 to 7.3) <0.0001
Base deficit
(normal range: -3.0 to 3.0 mmol/L)
3.9 (2.2 to 5.8) 7.6 (5.8 to 10.6) <0.0001
Data are presented as median and interquartile range or as mean ± standard deviation. Groups were compared using the Kruskal-Wallis test. aPTT, activated
partial thromboplastin time; MT, massive transfusion; n, number of patients; non-MT, non-massive transfusion; RBC, red blood cell concentrate.
Table 4 Coagulation parameters and their prediction of massive transfusion (MT)
ROC-AUC (95%
CI)
Optimum threshold (for best sensitivity and
specificity)
Sensitivity (95%
CI)
Specificity (95%
CI)
FIBTEM MCF 0.84 (0.79 to 0.88) ≤7 mm 77.5 (66.8 to 86.1) 74.9 (68.9 to 80.3)
FIBTEM A10 0.83 (0.78 to 0.87) ≤4 mm 63.3 (51.7 to 73.9) 83.2 (77.8 to 87.7)
EXTEM CT 0.71 (0.66 to 0.76) ≤72 s 76.3 (65.2 to 85.3) 59.4 (52.7 to 65.8)
EXTEM CFT 0.74 (0.68 to 0.79) ≤147 s 64.5 (52.7 to 75.1) 75.1 (69.0 to 80.6)
EXTEM MCF 0.76 (0.71 to 0.81) ≤52 mm 67.1 (55.4 to 77.5) 71.2 (64.8 to 77.0)
INTEM CT 0.71 (0.65 to 0.76) ≤167 s 65.3 (53.1 to 76.1) 75.5 (69.3 to 80.9)
INTEM CFT 0.78 (0.73 to 0.82) ≤111 s 75.0 (63.4 to 84.5) 67.3 (60.7 to 73.4)
INTEM MCF 0.78 (0.73 to 0.83) ≤51 mm 61.6 (49.5 to 72.8) 80.4 (74.5 to 85.3)
Platelet count 0.70 (0.65 to 0.75) ≤161 × 10
3/μl 62.0 (50.4 to 72.7) 73.8 (67.8 to 79.3)
Quick value 0.87 (0.83 to 0.90) ≤60% 84.8 (75.0 to 91.9) 82.1 (76.6 to 86.8)
aPTT 0.85 (0.81 to 0.89) ≤35.2 s 71.6 (59.9 to 81.5) 87.8 (82.8 to 91.7)
Fibrinogen
concentration
0.83 (0.78 to 0.87) ≤148 mg/dL 84.2 (74.0 to 91.6) 68.3 (61.8 to 74.3)
Hemoglobin 0.87 (0.83 to 0.91) ≤10.1 g/dL 77.5 (66.8 to 86.1) 84.5 (79.3 to 88.9)
Base deficit 0.76 (0.76 to 0.86) ≤6.3 69.6 (57.3 to 80.1) 79.8 (73.3 to 85.3)
pH 0.76 (0.70 to 0.81) ≤7.276 62.3 (49.8 to 73.7) 80.0 (73.6 to 85.4)
Lactate 0.74 (0.69 to 0.79) ≤4.18 mmol/L 54.9 (42.7 to 66.8) 88.0 (82.9 to 92.0)
A10, clot amplitude 10 minutes after CT; aPTT, activated partial thromboplastin time; CFT, clot formation time; CI, confidence interval; CT, clotting time; EXTEM,
extrinsically activated thromboelastometric test; FIBTEM, extrinsically activated thromboelastometric test with cytochalasin D; INTEM, intrinsically activated
thromboelastometric test; MCF, maximum clot firmness; ROC-AUC, area under the receiver operating characteristic curve.
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reported in a similar study by Leemann et al., where the
same definition for MT was used and patients’ demo-
graphic and clinical data were comparable [5]. Consider-
ing ROTEM
® parameters, elongated clot formation time
and reduced clot firmness (amplitude at specific time-
points and maximum clot firmness) were observed
among patients undergoing MT in both studies. The
ROC-AUC for INTEM MCF in the Leemann et al.
study (0.824) was comparable with that in the current
study (0.78). However, the Leemann et al.s t u d yd i dn o t
include FIBTEM parameters, which we report as provid-
ing better predictive value than other ROTEM
® para-
meters. Also, Leemann et al. reported mean RBC
transfusion during the first 24 hours of 22.3 units [5].
This is higher than the median of 15 units of RBCs in
our study, possibly attributable to a difference in coagu-
lation therapy. In our study, coagulation therapy was
based on fibrinogen and prothrombin complex concen-
trates, so that FFP was used only occasionally (10
patients out of 323). Our group has previously shown
that transfusion of RBC and platelet concentrate is sig-
nificantly lower when treating patients with coagulation
factor concentrate-based therapy, compared with FFP-
based therapy [21]. A more recent study by Davenport
et al. was performed to identify parameters for early
diagnosis of acute trauma-related coagulopathy [26].
This study reported reduced clot firmness (EXTEM
assay) among trauma patients with acute coagulopathy,
compared with non-coagulopathic patients. In line with
findings of the present study, Davenport et al.a l s o
reported that EXTEM clot amplitude at five minutes
may be used to predict which patients would require
MT [26], although as in the study by Leemann et al.,
the FIBTEM assay was not investigated.
Most trauma patients with major bleeding are coagu-
lopathic on admission to the ER, increasing the risk of
MT [6]. Early identification of patients who require MT
would enable appropriate blood products to be ordered
in advance. There is typically a time delay of up to an
hour between ordering FFP and having it at the bedside,
ready to administer [27,28]. Thus, by ordering an
appropriate quantity of FFP in advance, treatment time
delays may be minimized. This could have a significant
effect on patient outcomes: time to intervention appears
to impact mortality to a greater extent than the FFP:
RBC ratio [29].
We found that the initiation of coagulation (measured
by EXTEM and INTEM CT) and the kinetics of clot
formation (EXTEM and INTEM CFT) were prolonged
among MT patients compared with non-MT patients.
Furthermore, reduced clot quality (shown by lower
MCF in all ROTEM
® tests) was observed in the MT
group. Based on ROC curve data, FIBTEM MCF pro-
vides a higher predictive value for MT than other
ROTEM
® parameters. Importantly, the predictive value
of FIBTEM A10 was similarly high and, in addition,
there were no clinically relevant differences between the
median values for A10 and MCF. These findings high-
light the potential for FIBTEM to provide predictive
information within as little as 10 minutes after CT. This
f i n d i n gi sn o v e l :n op r e v i o u ss t u d yh a sa s s e s s e dt h e
potential of the FIBTEM assay to predict MT.
FIBTEM MCF or A10 is sometimes mistakenly con-
sidered as a means of measuring fibrinogen concentra-
tion. The FIBTEM assay measures elasticity of the
fibrin-based clot, which is dependent not only on fibri-
nogen but also on other proteins such as Factor XIII
[30]. Although correlations between FIBTEM MCF and
fibrinogen concentration have been observed [31-33],
the involvement of other proteins confounds extrapola-
tion between these parameters. Colloid therapy (for
example, hydroxyethyl starch (HES)) may be another
confounder, as the presence of HES reduces FIBTEM
values but increases Clauss fibrinogen concentration
[34]. Additional considerations are that any FIBTEM
amplitude below 2 mm is assigned a value of zero, and
that fibrinolysis may potentially impair formation of the
fibrin-based clot. These factors could all have contribu-
ted to our observation of zero FIBTEM A10 in 29
patients with fibrinogen concentrations up to 205 mg/
dL (Figure 2c).
In the current study, the highest ROC-AUC’sf o rM T
prediction were calculated for hemoglobin, Quick value
Table 5 RBC transfusion and coagulation therapy administered during the first 24 hours
non-MT group
(<10 RBC units/24 hours)
n = 245
MT group
(>10 RBC units/24 hours)
n=7 8
P-value
RBC (U) 2 (0 to 5) 15 (12 to 17) <0.0001
Fibrinogen concentrate (g) 0 (0 to 4) 10 (7 to 14) <0.0001
PCC (U) 0 (0 to 0) 2,400 (1,200 to 4,275) <0.0001
Platelet concentrate (U) 0 (0 to 0) 0 (0 to 2) <0.0001
MT, massive transfusion; n, number of patients; non-MT, non-massive transfusion; PCC, prothrombin complex concentrate; RBC, red blood cell concentrate; U,
units.
Data are presented as median and interquartile range. Groups were compared using the Mann-Whitney U-test.
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Page 7 of 11Figure 2 FIBTEM A10 and fibrinogen concentration on admission to the ER, and RBC transfusion. Low FIBTEM A10 (0 to 3 mm) and low
fibrinogen concentration (<100 mg/dL) upon ER admission was associated with an increased requirement for RBC transfusion. A10, clot
amplitude at 10 minutes after CT; ER, emergency room; FIBTEM, extrinsically activated thromboelastometric test with cytochalasin D; RBC, red
blood cell concentrate. (a)* P < 0.0001 vs 0 to 3 mm; (b)* P < 0.001 vs ≤100 mg/dL; **P < 0.0001 vs ≤100 mg/dL; (c) Correlation between
FIBTEM A10 and fibrinogen concentration rho = 0.75
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Page 8 of 11and aPTT. However, these tests are often only available
after a time delay of 30 to 60 minutes or more [9,10].
Point-of-care (POC) assessment of these parameters
may be undertaken, but at least for PT and aPTT this
has not been investigated for predicting MT. POC mea-
surement of fibrinogen has been attempted but this was
confounded by whole-blood constituents such as RBCs
and platelets [35]. Unlike ROTEM
® tests, laboratory
parameters cannot provide timely insight into overall
coagulation status or, therefore, provide valuable gui-
dance on the best therapy to administer. In view of this
and the lack of clinically important differences in pre-
dictive values for MT between FIBTEM A10/MCF and
the most predictive laboratory parameters, we advocate
prioritization of ROTEM
® analysis for trauma patients.
Time delay may explain why most scoring systems
developed for activating massive transfusion protocols
do not include standard coagulation tests [1,4,7,13]. For
example, the trauma associated severe hemorrhage
(TASH) score incorporates physiological parameters
(HR and systolic BP), laboratory test results which are
available within minutes (BD and hemoglobin), ana-
tomic findings (complex long bone fractures/pelvic frac-
ture; presence of intra-abdominal fluids) and gender.
Yucel et al. reported an ROC-AUC for TASH of 0.88, in
relation to prediction of MT [11]. Rainer et al. described
seven variables easy to obtain in the ER, and reported an
ROC-AUC for MT of 0.889 [4]. McLaughlin and cowor-
kers used SBP <110 mm Hg, heart rate >105 bpm, pH
<7.25 and hematocrit <32% to predict MT (ROC-AUC
0.74) [7]. The ABC score, reported by Nunez and Cot-
ton, comprises four components (penetrating injury, sys-
tolic blood pressure, heart rate, positive FAST) that can
be assessed within minutes (ROC-AUC 0.86) [12,13].
In contrast to these systems, ROTEM
® serves as a
rapid coagulation monitoring system with the additional
value of early MT risk stratification using the FIBTEM
A10 (ROC-AUC for MT: 0.83). Taken together, the three
ROTEM
® tests included in this study (INTEM, EXTEM,
FIBTEM) enable rapid detection of most coagulation dis-
orders [24,36]. These potentially include hyperfibrinoly-
sis, which cannot be assessed adequately by standard
coagulation tests, although it must be acknowledged that
no specific definition of hyperfibrinolysis based on
ROTEM
® parameters has yet been validated. INTEM,
EXTEM and FIBTEM are routinely performed in our ER,
and the ROTEM
® device allows them to be performed
simultaneously. The results may be used to facilitate
prompt, goal-directed coagulation therapy according to
the patient’s individual needs [20,21].
Limitations
The clinical value of the MT definition we used in this
study has been questioned: mortality increases with
increasing red blood cell transfusion (no apparent
threshold level of transfusion), so the criterion of 10
units in 24 hours does not allow specific selection of
patients with worsened clinical outcomes [37]. An alter-
native definition of MT has been explored (at least five
units of RBC during the first four hours) [38], but at
present there is not enough evidence to support the use
of such criteria.
MT patients in our study may not be directly compar-
able with those studied at other centres, due to our use
of coagulation factor concentrates for coagulation ther-
apy. Use of the standard FIBTEM assay also represents
a possible limitation of the study: it has been shown
that cytochalasin D does not provide complete inhibi-
tion of platelet activity [39]. As a result, in our study,
values for FIBTEM could be higher than they should be
and values for platelet component could be lower.
These effects would vary between patients depending on
platelet count. The retrospective nature of the study was
another limitation - for example, we were not able to
identify co-medications or co-morbidities that could
have influenced test results. As expected, the separation
of patients according to whether they underwent MT
led to groups of patients that were not balanced in rela-
tion to severity of injury. This imbalance could possibly
be considered as a study weakness, though on the other
hand it could be considered simply as a reflection of
clinical reality. The difference in patient numbers
between the two groups, which is attributable simply to
the number of patients meeting the inclusion criteria for
each group during the study period, might also be con-
sidered as a limitation of the study. We proceeded with
the analysis of the unbalanced groups because this
approach avoids the bias that might potentially arise
from the ‘artificial’ exclusion of a proportion of the non-
MT patients. Similar between-group differences, both in
patient numbers and severity of injury, were evident in
the study published by Leemann et al.[ 5 ] .L a s t l y ,t h e
exclusion of patients for whom therapy was withheld
d u et on o n - s u r v i v a b l ei n j u r i e sc o u l db ec o n s i d e r e da sa
limitation potentially introducing bias, as no patient
with the maximum ISS score of 75 was included in the
study. However, the inclusion of patients not receiving
standard medication would certainly have introduced
bias to the study, because they died without receiving
any transfusion and ROTEM
® test results would not
have been followed by any therapy.
Conclusions
In this retrospective study of trauma patients treated
with coagulation factor concentrates, FIBTEM A10 and
FIBTEM MCF obtained immediately after admission to
the ER provided early information on the likelihood of
requiring MT. Such prediction would allow early
Schöchl et al. Critical Care 2011, 15:R265
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activation of MT protocols. Through the use of a sin-
gle device, viscoelastic clot testing has the potential to
predict the risk of MT while also providing useful
information about the underlying coagulation disorder.
Taken together, these factors clearly distinguish
ROTEM
® from other means of predicting MT such as
hemoglobin level, Quick value or TASH score. Addi-
tional prospective studies are needed to confirm our
data.
Key messages
Early identification of the need for massive transfusion
(MT) may increase the speed and success of hemostatic
intervention in trauma patients.
FIBTEM MCF and FIBTEM A10 obtained from blood
samples taken immediately upon admission to the ER
showed similarly high predictive value for MT as the
most predictive laboratory parameters.
ROTEM
® analysis enables rapid detection of most
coagulation disorders; this study demonstrates the addi-
tional benefit of MT risk stratification using results
available within 10 minutes after CT.
Prospective trials are required to confirm the value of
ROTEM
® measurements in predicting massive
transfusion.
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